SCHEMBL303097

SCHEMBL303097

COc1cc2c(cc1OC)C(C)(C)/C(=C/c1ccccc1)C2=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.42
MAOB P27338 4/20 0.42
APP P05067 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
RET P07949 1/20 0.39
BCHE P06276 1/20 0.39
ABCB1 P08183 1/20 0.39
MAOA P21397 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29365202 1.00 ACHE (0.42) ACHEMAOBAPPKMT2AMEN1
SCHEMBL301682 1.00 ACHE (0.42) ACHEMAOBAPPKMT2AMEN1
SCHEMBL3044171 1.00 ACHE (0.42) ACHEMAOBAPPKMT2AMEN1
SCHEMBL15040995 0.94 ACHE (0.39) ACHEMAOBAPPKMT2AMEN1
SCHEMBL15040993 0.81 MAOB (0.38) MAOBKMT2AMEN1ALDH1A1MAPT
SCHEMBL15040971 0.81 MAOB (0.38) MAOBKMT2AMEN1ALDH1A1MAPT
SCHEMBL21098267 0.79 CA1 (0.41) ACHEMAOBAPPKMT2AMEN1
SCHEMBL12977425 0.78 MAPT (0.53) KMT2AMEN1ALDH1A1MAPTKDM4E
SCHEMBL12977423 0.78 MAPT (0.53) KMT2AMEN1ALDH1A1MAPTKDM4E
SCHEMBL16746500 0.77 HPGD (0.44) MAOBKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4103144-B1 COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS SYMRISE AG (DE) 2026-05-27 EP disclosed
EP-4110277-B1 COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS SYMRISE AG (DE) 2026-04-22 EP disclosed
EP-3045161-B1 Use of active mixtures of 1,2-hexanediol and 1,2-octanediol in cosmetic, pharmaceutical or dermatological emulsions SYMRISE AG (DE) 2026-03-25 EP disclosed
EP-4025675-B1 A PERFUME OIL MIXTURE SYMRISE AG (DE) 2026-03-18 EP disclosed
EP-4706780-A2 COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS Symrise AG (DE) 2026-03-11 EP disclosed
EP-4110276-B1 COMPOSITIONS COMPRISING ALKANEDIOLS SYMRISE AG (DE) 2026-01-28 EP disclosed
US-12421474-B2 Perfume oil mixture SYMRISE AG (DE) 2025-09-23 US disclosed
EP-4616840-A2 COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS WITH ANTIMICROBIALS FOR PRODUCT PROTECTION Symrise AG (DE) 2025-09-17 EP disclosed
US-12403076-B2 Compositions comprising odorless 1,2-pentanediol SYMRISE AG (DE) 2025-09-02 US disclosed
EP-4603149-A2 A PRESERVATIVE MIXTURE Symrise AG (DE) 2025-08-20 EP disclosed
WO-2010122178-A2 CYCLOHEXYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES SYMRISE GMBH & CO. KG (DE) 2010-10-28 WO disclosed
EP-2238968-A2 Skin treatment fighting skin aging Henkel AG & Co. KGaA (DE) 2010-10-13 EP disclosed
EP-2238967-A2 Skin treatment fighting skin aging II Henkel AG & Co. KGaA (DE) 2010-10-13 EP disclosed
WO-2010097479-A2 CYCLOHEXYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO. KG (DE) 2010-09-02 WO disclosed
WO-2010097480-A2 MENTHYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES SYMRISE GMBH & CO. KG (DE) 2010-09-02 WO disclosed
WO-2010089421-A2 MENTHYL CARBAMATE COMPOUNDS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO. KG (DE) 2010-08-12 WO disclosed
WO-2010070152-A2 USE OF DIHYDRODEHYDRODIISOEUGENOL AND PREPARATIONS COMPRISING DIHYDRODEHYDRODIISOEUGENOL SYMRISE GMBH & CO. KG (DE) 2010-06-24 WO disclosed
US-20090208433-A1 aryl hydrocarbon receptor (Ah receptor; AhR) antagonists such as 2-benzylidene-5,6-dimethoxy-3H-inden-1-one, used for preventing a translocation of an AhR into a cell nucleus, ultraviolet radiation-induced gene expression or skin damage; cosmetics; sunscreen agents; aldol condensation SYMRISE GMBH & CO., KG (DE) 2009-08-20 US disclosed
US-20090208433-A1 aryl hydrocarbon receptor (Ah receptor; AhR) antagonists such as 2-benzylidene-5,6-dimethoxy-3H-inden-1-one, used for preventing a translocation of an AhR into a cell nucleus, ultraviolet radiation-induced gene expression or skin damage; cosmetics; sunscreen agents; aldol condensation SYMRISE GMBH & CO., KG (DE) 2009-08-20 US disclosed
WO-2007128723-A1 AH RECEPTOR ANTAGONISTS SYMRISE GMBH & CO. KG (DE) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208433-A1 aryl hydrocarbon receptor (Ah receptor; AhR) antagonists such as 2-benzylidene-5,6-dimethoxy-3H-inden-1-one, used for preventing a translocation of an AhR into a cell nucleus, ultraviolet radiation-induced gene expression or skin damage; cosmetics; sunscreen agents; aldol condensation AHR, ARNT, AIPL1 ACHE 4669/4885MAOB 1847/4885APP 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.